MEDSNasdaqWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends December 31

DataMeds AI, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 17, 2026

$2.67+0.04 (+1.52%)

Close on Oct 19, 2026

Market cap: $6.87M
P/E (TTM): –
Dividend yield: –

Dividends

DataMeds AI has not reported a dividend

No dividend per share appears in DataMeds AI's annual filings since fiscal 2022.

Where these numbers come from

Parsed from the XBRL in DataMeds AI's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-50 reverse split on Aug 17, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is MEDS.

Revenue growth-78.2% · median -48.1%

Gross margin-90.6% · median 34.8%

Operating margin-875.7% · median -100.8%

Net margin-1100.3% · median -419.8%

Company	Revenue	Growth
COSM	$73.73M	+33.8%
MEDS	$8.02M	-78.2%
STEK	$2.40M	-38.6%
NASC	$1.03M	-57.7%
ESYN	$389.74K	-68.5%
HKPD	–	–

Company

Next earnings (est.): Nov 19, 2026, after close
Exchange: Nasdaq
Industry: Wholesale-Drugs, Proprietaries & Druggists' Sundries
Fiscal year ends: December 31
Employees: 35
Held by institutions: 1.7%
Auditor: Suri & Co., Chartered Accountants
SEC CIK: 2030763

Advertisement
300 × 250